A Phase 2 interventional study of RO5024048 and danoprevir in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 27 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-08-01.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing danoprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. danoprevir · Hepatitis C, Chronic.
Among the 10 studies testing danoprevir in Hepatitis C, Chronic, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 5th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 10 studies testing danoprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 79 across the 10 interventional studies. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 50th largest by enrollment of the 59 interventional ones that give a count, is one of 10 that started in 2012, is one of 16 in phase 2, and was the 56th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing danoprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, parallel cohort study will evaluate the safety, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients, and with RO5024048 added to the combination treatment in prior null responder patients with chronic hepatitis C genotype 1 or 4 and compensated cirrhosis. All patients will receive danoprevir 100 mg orally twice daily (bid) , ritonavir 100 mg orally bid, Pegasys 180 mcg subcutaneously weekly and ribavirin 1000-1200 mg/kg/day orally. Prior non-responders will receive RO5024048 1000 mg orally bid additionally. Anticipated time on study treatment is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
Drug: danoprevir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin · Drug: ritonavir
RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys \[peginterferon alfa-2a\] and ribavirin) in prior null responder patients
Drug: RO5024048 · Drug: danoprevir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin · Drug: ritonavir
1000 mg orally bid, 24 weeks
100 mg orally bid, 24 weeks
180 mcg weekly, 24 weeks
1000-1200 mg/kg/day orally in two divided doses, 24 weeks
100 mg orally bid, 24 weeks
Safety: Incidence of adverse events
Time frame: 48 weeks
Pharmacokinetics (PK): Area under the concentration-time curve (AUC)
Time frame: Intensive PK sample collection during initial 2 week dosing period, followed by routine sampling during treatment up to Week 24
Antiviral activity: Hepatitis C virus (HCV) RNA levels assessed by Roche COBAS Taqman HCV Test
Time frame: 48 weeks
Emergence of viral resistance: HCV RNA gene sequence variations
Time frame: From baseline to Week 48
Virologic response: HCV RNA levels
Time frame: approximately 1 year
The record gives a start of Apr 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Danoprevir · Ritonavir